Holen Sie sich die Stockscreener-App
100.93
0.42%
0.4867
Schlusskurs vom Vortag:
$100.44
Offen:
$100.45
24-Stunden-Volumen:
170.97K
Relative Volume:
0.13
Marktkapitalisierung:
$6.59B
Einnahmen:
$1.54B
Nettoeinkommen (Verlust:
$233.56M
KGV:
29.98
EPS:
3.3669
Netto-Cashflow:
$348.64M
1W Leistung:
+0.05%
1M Leistung:
-0.08%
6M Leistung:
+26.07%
1J Leistung:
+83.16%
1-Tages-Spanne:
$100.45
$100.93
1-Wochen-Bereich:
$100.37
$101.00
52-Wochen-Spanne:
$49.67
$111.86
Lantheus Holdings Inc Stock (LNTH) Company Profile
Firmenname
Lantheus Holdings Inc
Sektor
Telefon
978 671-8001
Adresse
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
100.93 | 6.56B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
18.25 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.81 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.19 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.58 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.10 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-12-12 | Hochstufung | Truist | Hold → Buy |
| 2025-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2025-08-12 | Herabstufung | Truist | Buy → Hold |
| 2024-12-18 | Eingeleitet | Goldman | Buy |
| 2024-09-03 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-07-10 | Bestätigt | JMP Securities | Mkt Outperform |
| 2023-12-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-12-04 | Eingeleitet | TD Cowen | Outperform |
| 2023-09-29 | Eingeleitet | William Blair | Outperform |
| 2023-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-11-30 | Eingeleitet | SVB Leerink | Outperform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-05-09 | Eingeleitet | B. Riley Securities | Buy |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2021-02-01 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-29 | Fortgesetzt | Jefferies | Buy |
| 2019-08-16 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2017-11-02 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-11-08 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-09-23 | Fortgesetzt | Credit Suisse | Neutral |
| 2016-02-24 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-12-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2015-09-30 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2015-07-20 | Eingeleitet | Credit Suisse | Outperform |
| 2015-07-20 | Eingeleitet | Jefferies | Buy |
| 2015-07-20 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2015-07-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-20 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Lantheus Holdings Inc Aktie (LNTH) Neueste Nachrichten
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Entities Hold 20.9% Stake in Radiopharm Theranostics (NASDAQ: RADX) Including Significant Options - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Lantheus (NASDAQ: LNTH) holders to vote on cash buyout with potential bonus payout - Stock Titan
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring Growth Potential in the Healthcare Sector - DirectorsTalk Interviews
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value - Stocktwits
Lantheus alpha therapy, CATX director, sells $131k in stock By Investing.com - Investing.com Australia
Lantheus alpha therapy, CATX director, sells $131k in stock - Investing.com
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - kalkinemedia.com
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 35,769 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells 35K shares, still owns 11.6M - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 78,145 Shares - GuruFocus
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock - Investing.com
Technical Reactions to LNTH Trends in Macro Strategies - Stock Traders Daily
Lantheus Holdings, Inc. (LNTH): Analyst Consensus and Growth Potential Amid Healthcare Innovations - DirectorsTalk Interviews
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lanth - The National Law Review
Lantheus Holdings 1Q Net $118.4M >LNTH - Moomoo
LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring a 7% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Healthcare Equipment and Supplies Stocks Q2 Recap: Benchmarking Lantheus (NASDAQ:LNTH) - Yahoo Finance
Lantheus (LNTH) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in Latest Trading; Session Move - Vinanet
Lantheus Holdings CAO Kimberly Brown Sells 463 Shares for Tax Withholding Purposes - Kalkine Media
Lantheus Holdings, Inc. Stock 12‑Month Price Target Cut to $106.3, Implies 6% Upside - TradingView
Lantheus (LNTH) Q2 2026 Filing Snapshot: The EPS Result Is Above Expectation in the Current Update; Market Follow-Through: The Stock Records a 0.64% Decrease on the DayInvestor Earnings Call - Vinanet
Lantheus Wins FDA Approval for Alzheimer's Tau PET Imaging Agent - finance.biggo.com
B.Riley downgrades Lantheus stock rating on Curium acquisition By Investing.com - Investing.com Australia
B.Riley downgrades Lantheus stock rating on Curium acquisition - Investing.com Nigeria
FDA approves Lantheus tau PET imaging agent for Alzheimer’s disease - DOTmed
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A Healthcare Powerhouse with 6.21% Potential Upside - DirectorsTalk Interviews
Tauklarify PET approval for Lantheus in AD NFT pathology - pharmaphorum
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics - Sahm
What Does Lantheus Holdings (LNTH) FDA Approval Mean For Its Alzheimer’s Push? - webull.com
Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals - RTTNews
US FDA approves Lantheus’ brain-imaging agent for Alzheimer’s assessment - KWSN
LNTH Looks 10.1% Overvalued on GF Value™ - GuruFocus
US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment - Reuters
Lantheus Wins FDA Approval for Alzheimer's Tau Imaging Agent Tauklarify - marketscreener.com
Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s - Seeking Alpha
FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease - Investing.com
FDA approves Lantheus’ tau imaging agent for Alzheimer’s disease By Investing.com - Investing.com Nigeria
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease - The Manila Times
Finanzdaten der Lantheus Holdings Inc-Aktie (LNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantheus Holdings Inc-Aktie (LNTH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10% Owner |
Sep 03 '26 |
Sale |
3.11 |
80,783 |
250,896 |
11,440,513 |
| Lantheus Alpha Therapy, LLC | 10% Owner |
Sep 02 '26 |
Sale |
3.11 |
42,129 |
131,219 |
11,521,296 |
| Lantheus Holdings, Inc. | 10% Owner |
Sep 01 '26 |
Sale |
3.12 |
35,769 |
111,574 |
11,563,425 |
| Lantheus Holdings, Inc. | 10% Owner |
Aug 31 '26 |
Sale |
3.14 |
78,145 |
245,610 |
11,599,194 |
0.22%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):